Guardant Health Investor Presentation
Focused on expanding the scope of precision oncology
Limitations of
Current
Approaches
Patient
Impact
Therapy Selection
Late-stage cancer patients
Tissue Availability and
Exhaustion
Delay in Care
8% ********
iii
of advanced NSCLC patients are
tested for biomarkers in line with
the NCCN Guidelines
Recurrence Monitoring
Cancer survivors
Early Detection
Asymptomatic individuals
No Tissue Available
High False Positive Rate
Symptomatic Intervention.
Low Compliance
56% tttttttt
of colon cancer patients referred
for disease recurrence have not
had a recurrence
38% tttttttt
of NSCLC patients are diagnosed
with early stage disease
GUARDANT
Our
Solution
360°
Commercial 2014
MNI
Commercial 2017
for research use
LUNAR-1
LUNAR- 2
Rebecca L. Siegel, Cancer Statistics, 2018, A Cancer Journal for Clinicals, Gutierrez et al. 2017 Clinical Lung Cancer, PLOS ONE | DOI:10.1371/journal.pone.0171810
5
GUARDANTView entire presentation